Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
254.55 INR | -0.86% |
|
-3.23% | -14.19% |
30/06 | Marksans Pharma Receives EIR From USFDA for Time-Cap Labs Facility in New York | MT |
19/06 | Marksans Pharma Receives Marketing Authorization For Oxybutynin Hydrochloride Oral Solution | RE |
Capitalization | 12TCr 134.48Cr 115.02Cr 107.24Cr 100Cr 184.14Cr 204.81Cr 1.29TCr 490.45Cr 5.4TCr 504.31Cr 493.94Cr 20TCr | P/E ratio 2025 |
26.5x | P/E ratio 2026 * | 23.7x |
---|---|---|---|---|---|
Enterprise value | 12TCr 134.48Cr 115.02Cr 107.24Cr 100Cr 184.14Cr 204.81Cr 1.29TCr 490.45Cr 5.4TCr 504.31Cr 493.94Cr 20TCr | EV / Sales 2025 |
3.84x | EV / Sales 2026 * | 3.66x |
Free-Float |
53.65% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Marksans Pharma Limited
1 day | -0.86% | ||
1 week | -3.23% | ||
Current month | -2.66% | ||
1 month | -2.08% | ||
3 months | +23.82% | ||
6 months | -2.28% | ||
Current year | -14.19% |
1 week | 249.5 | ![]() | 266.6 |
1 month | 235.9 | ![]() | 266.6 |
Current year | 171 | ![]() | 306.9 |
1 year | 171 | ![]() | 358.7 |
3 years | 45.4 | ![]() | 358.7 |
5 years | 34.35 | ![]() | 358.7 |
10 years | 9.85 | ![]() | 358.7 |
Manager | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 06/10/2005 | |
Director of Finance/CFO | 56 | 06/09/2002 | |
Compliance Officer | - | - |
Director | Title | Age | Since |
---|---|---|---|
Chairman | 53 | 06/10/2015 | |
Director/Board Member | 53 | 25/09/2014 | |
Director/Board Member | 71 | 11/07/2019 |
Name | Weight | AuM | 1st Jan change | |
---|---|---|---|---|
0% | 89 M€ | -0.33% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.86% | -3.23% | +34.57% | +422.69% | 134.44Cr | ||
+0.30% | +1.58% | -16.38% | +145.07% | 71TCr | ||
-0.50% | +0.57% | +4.68% | -10.78% | 38TCr | ||
-1.31% | +1.67% | +13.02% | +26.23% | 34TCr | ||
-3.64% | -2.74% | -55.22% | +8.38% | 31TCr | ||
-2.36% | -1.23% | +0.78% | -21.80% | 26TCr | ||
-3.00% | -1.93% | -3.83% | +16.05% | 24TCr | ||
-1.66% | +1.10% | -14.76% | -6.40% | 22TCr | ||
-0.79% | +3.00% | -34.75% | -10.94% | 21TCr | ||
-1.70% | -1.00% | -10.75% | +19.56% | 16TCr | ||
Average | -1.55% | +0.39% | -8.26% | +58.81% | 28.18TCr | |
Weighted average by Cap. | -1.30% | +0.64% | -12.49% | +38.61% |
2025 | 2026 * | |
---|---|---|
Net sales | 2.62TCr 30Cr 26Cr 24Cr 23Cr 42Cr 46Cr 292.04Cr 111.2Cr 1.22TCr 114.34Cr 111.99Cr 4.5TCr | 3.15TCr 37Cr 31Cr 29Cr 27Cr 50Cr 56Cr 351.54Cr 133.86Cr 1.47TCr 137.64Cr 134.81Cr 5.41TCr |
Net income | 388.3Cr 4.53Cr 3.87Cr 3.61Cr 3.35Cr 6.2Cr 6.89Cr 43Cr 17Cr 181.65Cr 17Cr 17Cr 667.53Cr | 486.65Cr 5.67Cr 4.85Cr 4.52Cr 4.2Cr 7.77Cr 8.64Cr 54Cr 21Cr 227.66Cr 21Cr 21Cr 836.6Cr |
Net Debt | - | - |
More financial data
* Estimated data
Employees
1,141
Sector
Pharmaceuticals
Calendar
Date | Price | Change | Volume |
---|---|---|---|
11/25/11 | 254.55 ₹ | -0.86% | 12,43,743 |
10/25/10 | 256.75 ₹ | -0.81% | 4,65,844 |
09/25/09 | 258.85 ₹ | +2.54% | 10,79,028 |
08/25/08 | 252.45 ₹ | -1.92% | 9,98,015 |
07/25/07 | 257.40 ₹ | -2.15% | 8,96,682 |
Delayed Quote NSE India S.E., July 11, 2025 at 05:19 pm IST
More quotesSell
Buy

Mean consensus
BUY
Number of Analysts
3
Last Close Price
254.55INR
Average target price
301.00INR
Spread / Average Target
+18.25%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MARKSANS Stock
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition